IP Strategy for the Chemical Industry: What Innovators Need to Know

The chemical industry rarely gets the spotlight that pharma or tech does, but it’s one of the most IP-dense fields in the world. Every new polymer, catalyst, formulation, or manufacturing process that makes it to market usually comes with a layer of intellectual property strategy behind it, not just a patent, but decisions about what to search for, what to protect, what to brand, and what to keep as a trade secret.

This post walks through what patentability looks like in chemicals, how the rest of the IP toolkit applies to the field, where innovation is happening right now, and how a firm like PATHtoIP fits into that process.

What Makes a Chemical Invention Patentable

The Three Basic Tests

Not every new compound or process clears the bar on its own. Patent offices, in India, the US, Europe, or elsewhere, generally look for three things:

• Novelty: the invention shouldn’t already exist in public knowledge, anywhere in the world.
• Inventive step (non-obviousness): it shouldn’t be something a skilled chemist would arrive at through routine experimentation.
• Industrial applicability: it needs to be usable, not just theoretical.

What Typically Gets Filed

In chemicals specifically, patentable subject matter tends to fall into a few buckets:

• New compounds or compositions: a novel molecule, alloy, or formulation
• Processes: a new or significantly improved way of manufacturing an existing substance, often more valuable than the compound itself, since process efficiency drives cost
• New uses of known substances: a known compound found to work for an entirely different application
• Formulations and mixtures: particularly common in specialty chemicals, coatings, and agrochemicals

One nuance specific to chemistry: a slight structural variation, or a new use of a known compound, can be patentable, but it has to clear a higher bar of proving the result was genuinely unexpected, not just an incremental tweak. This is where a large share of chemical patent applications get rejected, in India and the US alike.

It Starts Before Drafting: Search and Freedom to Operate

A patentability search maps the existing landscape, prior patents, publications, and disclosures, to check whether the invention is genuinely novel and to understand how it may need to be positioned to clear examination.

Freedom to Operate (FTO) analysis asks a separate question entirely: even if your invention is patentable, does making, using, or selling it infringe someone else’s active patent? In chemicals, where processes and formulations often build on decades of prior industrial chemistry, FTO clearance can matter more than the patent itself before a product launches.

Skipping either step is one of the more common and expensive  mistakes chemical companies make when moving from lab to market.

Patentability Compared: India, the US, and Europe

Chemical patentability standards diverge more sharply across these jurisdictions than in almost any other technology area. A claim set drafted for one can fail in another if it isn’t adapted.

What a Markush claim actually looks like: The term gets used often but is rarely shown. A Markush claim covers a genus of related compounds by defining a core structure with variable substituent positions, rather than listing every compound individually. A generic, illustrative example, not drawn from any real filing, might read:

1. A compound of Formula (I):

    R₁–Q–R₂

    (Formula I)

or a pharmaceutically acceptable salt thereof, wherein: Q is selected from the group consisting of CH₂-; R₁ is selected from the group consisting of hydrogen, alkyl, and phenyl; and R₂ is selected from the group consisting of halogen, like Cl, F etc.

This single claim, on its face, can cover thousands of individual compounds, every permutation of Q, R₁, and R₂. That breadth is exactly what makes Markush claims valuable and exactly what makes them fragile: a single prior-art disclosure of any one combination within the claimed genus can be cited against the entire claim, and as the table above shows, India, the US, and the EPO each test how much of that genus the specification actually needs to “enable” or “support” differently. A genus this broad, filed without worked examples spanning its range, is precisely the kind of claim that survives drafting but doesn’t survive examination.

Patentability and FTO ask two different questions about the same claim and Markush claims are where that distinction matters most.

Patentability asks whether you can get this claim granted:

• Novelty across the whole genus: a single prior-art reference disclosing even one combination within the claimed space (say, Q = CH₂-, R₁ = methyl, R₂ = chlorine) can destroy novelty of the entire genus unless it’s expressly disclaimed.
• Inventive step: would a skilled chemist arrives at this genus through routine optimizatwion of a known lead compound, or does the structure-activity data show a genuinely unexpected result?
• Enablement/sufficiency (US §112, EPO Art. 83, India §10(4)): does the specification support the full breadth claimed, or only a handful of worked examples inside a much larger substituent list? This is where broad Markush claims most often fail post-Amgen v. Sanofi.
• Section 3(d): if a variation amounts to a “new form” of an already-known base compound, India additionally requires enhanced efficacy data.
• Claim clarity: Markush language needs closed terms (“consisting of”) so R₁ and R₂ boundaries are definite, not open-ended.

Freedom to Operate asks whether someone else can already block you from making, using, or selling within that genus, a separate question a granted patent of your own doesn’t answer:

• Search for active, in-force blocking patents whose claims read on the specific R₁/Q//R₂ combination you intend to commercialize, not the whole genus you’ve claimed.
• Check the actual embodiment you’ll sell, not just the core scaffold, a specific salt, polymorph, formulation, or second medical use may be separately patented even where the parent genus is clear.
• Read the prosecution history, a competitor’s broad genus claim may have been narrowed by amendment during examination, so granted scope can be meaningfully smaller than what was originally filed.
• Run it per jurisdiction, a blocking Markush patent active in the US has no bearing in India unless an equivalent is granted there.
• Treat process and product FTO separately, a process patent on how to make a compound within your genus can block manufacturing even when the product itself is clear.
• Confirm legal status, a lapsed, invalidated, or opposed patent may no longer block you at all.

The distinction worth keeping in front of any team: patentability asks whether you can exclude others from your claimed genus; FTO asks whether someone else can already exclude you from part of it. A company can hold a strong, validly granted Markush patent and still be blocked from commercializing a specific compound within it by someone else’s earlier, or even broader, patent.

Section 3(d) is what chemical innovators filing in India need to understand from the outset. It specifically bars patents on new forms of already-known substances, polymorphs, salts, isomers, unless the applicant can show the new form is significantly more efficacious, not just different. The rule exists to stop “evergreening.” The practical effect is that claim strategy for the Indian market often has to be built differently, and earlier, than a US or EP filing built on the same underlying chemistry, the efficacy data needs to be in the specification, not retrofitted later.

Where Innovation Is Actually Happening

A few areas are generating a disproportionate share of chemical IP activity right now:

• Sustainable chemistry: biodegradable polymers, solvent-free processes, carbon capture materials
• Battery and energy storage chemistry: electrolyte formulations, cathode materials, solid-state battery components
• Specialty and performance chemicals: coatings, adhesives, materials engineered for industrial use
• Agrochemicals: formulations balancing efficacy against environmental impact

Before committing R&D budget to any of these, it’s worth running a technology landscape or white space analysis, essentially a map of what’s already been filed in an area, showing which zones are crowded and where genuine openings exist.

Protecting the Product from Every Angle

A single chemical product is rarely protected by just one type of IP. Different parts of the same product usually need different tools, often simultaneously:

• Patents protect the invention itself, a new compound, formulation, or manufacturing process. This is the default choice when the invention would be identifiable or reverse-engineerable once the product is on the market. The Haber-Bosch process for synthesizing ammonia is a classic illustration: BASF’s early-1900s patent protected the method of production, not the compound, since ammonia itself was already known.
• Trade secrets protect process know-how that stays hidden even after the product ships, things a competitor can’t reverse-engineer just by testing what’s on the shelf. WD-40 is the standard chemical-industry example: its exact formulation has never been patented and is held as a trade secret to this day, precisely because a patent would have required disclosing it publicly.
• Trademarks protect the brand, a product name, logo, or packaging that identifies the company as the source. Teflon and Kevlar (DuPont) illustrate the point well: the underlying chemistry behind both is long out of patent, but the brand names remain protected and are still what customers associate with quality and origin.
• Geographical indications (GIs) protect products whose identity is tied to where they’re made. Makrana Marble from Rajasthan, GI-tagged because its distinct mineral composition and quality are specifically linked to that region, and the marble the Taj Mahal was built from — is a fitting chemical-industry-adjacent example.

The earliest strategic decision, often made before any drafting begins, is which of these actually fits. Processes that are hard to reverse-engineer sometimes make better trade secrets than patents. Compounds and formulations that will inevitably be identified through analysis of the marketed product are usually better protected as patents. Brand elements almost always deserve trademark protection regardless of which route the underlying chemistry takes.

What This Means for Filing Strategy

• File claim sets tailored per jurisdiction, not one global set, a genus claim built to survive EPO sufficiency requirements may still fail India’s Section 3(d) efficacy bar for a polymorph embodiment, and vice versa.
• Building enhanced-efficacy and unexpected-result data into the specification from day one, especially for India- and EPO-bound filings, retrofitting it after an office action is far harder than anticipating it during drafting.
• Reassess genus/Markush claim scope for pending or planned US filings in light of Amgen v. Sanofi, claims enabling only a few representative species within a broad genus are now considerably more exposed.
• Treat EPO opposition and India’s compulsory-licensing exposure (tied to Form 27 disclosures) as filing-stage strategic considerations, not afterthoughts.

How PATHtoIP Helps

Chemical companies rarely need just one of these services in isolation, most inventions move through several of them in sequence. PATHtoIP supports chemical innovators across the full path:

• Patentability searches to confirm novelty before committing R&D and drafting resources to an idea
• Freedom to Operate analysis before a product launch, to flag active patents that could block manufacturing or sale
• Patent drafting and filing for compounds, formulations, and processes, in India and internationally
• Trademark and GI filing for product names, brands, and region-linked chemical or agricultural products
• Technology landscape and white space analysis to guide where R&D investment is likely to pay off

Stay connected with PATHtoIP for the latest insights on patents, trademarks, copyrights, innovation, and IP strategy. Follow us on LinkedIn, Instagram, Facebook, X , Pinterest, YouTube, and Quora for expert guidance, industry updates, case studies, and practical tips to protect your innovations.